Preventing Alzheimer's disease progression


AZTherapies, Inc, a privately-held drug development company headquartered in Boston, MA, is developing breakthrough combination drug therapies to prevent and to manage disease progression in persons with mild cognitive impairment (MCI) and with early-to-moderate Alzheimer’s disease. AZTherapies is preparing to launch a Phase II/III trial of a proprietary disease modifying treatment for Alzheimer’s disease.

Our Programs

ALZT-OP pipeline

Easily administered small molecule drugs to prevent Alzheimer's progression and pathogenesis.


Eliminating missed and improper dosage for Alzheimer's patients.